---
id: 212
title: Urethritis and Cervicitis
category: clinical_syndromes
subcategory: sexually_transmitted
tags: [urethritis, cervicitis, gonorrhea, chlamydia, NGU, ceftriaxone, doxycycline]
difficulty: medium
---

## Question

How are urethritis and cervicitis managed? Use **"Ceftriaxone 500mg IM × 1 + Doxycycline 100mg BID × 7d (Cover GC + CT)"** framework.

## Answer

### **Definitions:**

**Urethritis:**
- **Urethral inflammation** → dysuria, discharge
- **Non-gonococcal urethritis (NGU):** *Chlamydia*, *Mycoplasma*, *Ureaplasma*
- **Gonococcal urethritis (GU):** *Neisseria gonorrhoeae*

**Cervicitis:**
- **Cervical inflammation** → mucopurulent discharge, friability
- **Often asymptomatic**

### **Clinical Presentation:**

**Urethritis (Men):**
- **Dysuria, urethral discharge** (purulent if GC, clear/mucoid if NGU)
- **Physical exam:** Urethral discharge on milking urethra

**Cervicitis (Women):**
- **Often asymptomatic** (50-70%)
- **Mucopurulent discharge, cervical friability, bleeding**
- **Dysuria, vaginal discharge** (non-specific)

### **Diagnosis:**

**Urethritis (Men):**
- **≥1 of:**
  - Urethral discharge
  - ≥5 WBC per HPF on urethral smear
  - Positive leukocyte esterase on first-void urine OR ≥10 WBC/HPF on microscopy

**Cervicitis (Women):**
- **≥1 of:**
  - Mucopurulent discharge from cervical os
  - Cervical friability (bleeds easily with swab)
  - ≥10 WBC per HPF on endocervical smear

**NAAT Testing (Preferred):**
- ***Neisseria gonorrhoeae* + *Chlamydia trachomatis* NAAT**
- **Specimens:**
  - **Men:** First-void urine (preferred, non-invasive) OR urethral swab
  - **Women:** Vaginal swab (self/provider-collected, most sensitive) OR endocervical swab OR urine

**Do NOT wait for results** - treat empirically if clinical diagnosis

### **Microbiology:**

***Chlamydia trachomatis* (CT):**
- **Most common bacterial STI** (US)
- **NGU:** 30-50% of cases

***Neisseria gonorrhoeae* (GC):**
- **Gonococcal urethritis/cervicitis**
- **Increasing cephalosporin resistance**

***Mycoplasma genitalium*:**
- **NGU:** 15-25% of cases
- **Increasing macrolide resistance**
- **Test if available** (but NAAT not widely available)

***Ureaplasma urealyticum*:**
- **NGU:** 20-30%

***Trichomonas vaginalis*:**
- **NGU:** 10-20%
- **Test if available**

### **Treatment:**

**Empiric Treatment (Cover GC + CT):**

**Recommended:**
- **Ceftriaxone 500mg IM × 1** (1g if body weight ≥150 kg)
- **+ Doxycycline 100mg PO BID × 7 days**

**Alternative (If Ceftriaxone Not Available):**
- **Cefixime 800mg PO × 1** (less effective than ceftriaxone, use only if no IM option)
- **+ Doxycycline 100mg PO BID × 7 days**

**If Doxycycline Contraindicated (Pregnancy):**
- **Ceftriaxone 500mg IM × 1**
- **+ Azithromycin 1g PO × 1** (but higher failure rate for *C. trachomatis*, prefer doxycycline if not pregnant)

**Pathogen-Specific Treatment:**

***Chlamydia trachomatis*:**
- **Doxycycline 100mg PO BID × 7 days** (preferred, ~97% cure)
- **Azithromycin 1g PO × 1** (convenience, but ~95% cure, use if adherence concern)

***Neisseria gonorrhoeae*:**
- **Ceftriaxone 500mg IM × 1** (1g if ≥150 kg)
- **Do NOT use cefixime alone** (less effective, increasing resistance)
- **Dual therapy with doxycycline** (covers *Chlamydia* co-infection, may ↓GC resistance)

***Mycoplasma genitalium* (Persistent NGU After Doxycycline):**
- **Moxifloxacin 400mg PO daily × 7 days** (if macrolide resistance suspected)
- **Azithromycin 1g PO × 1, then 500mg PO daily × 3 days** (extended regimen)

***Trichomonas vaginalis*:**
- **Metronidazole 2g PO × 1** OR **500mg PO BID × 7 days**
- **Tinidazole 2g PO × 1**

### **Follow-Up:**

**Test of Cure (TOC) NOT Routinely Recommended:**
- **Exceptions:** Pregnancy, persistent symptoms, pharyngeal GC (retest in 7-14 days)

**Retest in 3 Months:**
- **High reinfection rate** (~20%)
- **NAAT for GC + CT** at 3 months

**Persistent Symptoms:**
- **If symptoms persist >7 days after treatment:**
  - **Re-evaluate for:** Treatment failure, reinfection, *M. genitalium*, *T. vaginalis*
  - **Consider moxifloxacin** (if *M. genitalium* suspected)

### **Partner Management:**

**Expedited Partner Therapy (EPT):**
- **Provide treatment to partners** without examination
- **Give partner:** Doxycycline 100mg BID × 7 days OR azithromycin 1g × 1
- **Legal in most US states** (check local regulations)

**All Partners Within 60 Days:**
- **Treat all partners** from last 60 days (or most recent if >60 days)

### **Complications:**

**Women:**
- **Pelvic inflammatory disease (PID)** (10-20% if untreated *Chlamydia*/GC)
- **Infertility, ectopic pregnancy, chronic pelvic pain**
- **Perihepatitis (Fitz-Hugh-Curtis syndrome)**

**Men:**
- **Epididymitis**
- **Reactive arthritis** (especially if HLA-B27+)

**Pregnancy:**
- **Preterm birth, low birth weight, neonatal conjunctivitis/pneumonia**

### **Special Situations:**

**Pregnancy:**
- **Screen all pregnant women** (1st trimester, repeat 3rd trimester if high risk)
- **Treatment:** Ceftriaxone 500mg IM × 1 + **azithromycin 1g PO × 1** (avoid doxycycline)

**HIV-Positive:**
- **Same treatment**
- **Higher rates of co-infection** (screen regularly)

**Adolescents:**
- **Highest incidence** (screen annually if sexually active)

## Key Points

### **Empiric = Ceftriaxone + Doxycycline:**
- **Ceftriaxone 500mg IM × 1** + **doxycycline 100mg BID × 7 days**
- **Covers GC + CT** (co-infection in 10-40%)

### **Doxycycline > Azithromycin for *Chlamydia*:**
- **Doxycycline 97% cure** vs **azithromycin 95%**
- **Use azithromycin** only if adherence concern, pregnancy

### **Do NOT Use Cefixime Alone:**
- **Increasing GC resistance**
- **Ceftriaxone IM preferred** (500mg, or 1g if ≥150 kg)

### **Retest at 3 Months:**
- **High reinfection rate** (~20%)

### **Expedited Partner Therapy (EPT):**
- **Provide treatment to partners** without exam (legal in most states)

### **Clinical Pearls:**
- **Empiric:** Ceftriaxone 500mg IM × 1 + doxycycline 100mg BID × 7 days
- **Co-infection common** (10-40% GC + CT)
- **Doxycycline preferred** over azithromycin for *Chlamydia*
- **Retest at 3 months** (high reinfection rate)
- **EPT:** Treat partners without exam
- **Pregnancy:** Ceftriaxone + azithromycin (avoid doxycycline)

## Sources

- [CDC: Sexually Transmitted Infections Treatment Guidelines 2024]
- [MMWR: Gonorrhea Treatment Update 2024]

## Media

N/A
